Retrophin (RTRX) Names Margaret Valeur-Jensen, Ph.D. As General Counsel

NEW YORK--(BUSINESS WIRE)--Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of Margaret Valeur-Jensen, Ph.D. to the newly created position of General Counsel, effective immediately. She will be responsible for providing legal advice regarding the Company's commercial operations, research activities, business development and compliance with industry standards.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.